双歧杆菌三联活菌联合保肝治疗对乙肝肝硬化患者血清炎性因子水平及肠道菌群的影响

Effects of Bifidobacterium Bifidum Triplex Combined with Hepatoprotective Therapy on Serum Inflammatory Factor Levels and Intestinal Flora in Patients with Hepatitis B Cirrhosis

目的 分析在治疗乙型病毒性肝炎(以下简称“乙肝”)肝硬化中进行双歧杆菌三联活菌结合保肝治疗的效果。方法 选取2020年3月—2023年3月海南医学院附属第一医院收治的92例乙肝肝硬化患者作为研究对象,利用最新统计学软件生成随机序列后分为对照组、观察组,各46例。对照组采取保肝治疗,观察组同时采取双歧杆菌三联活菌和保肝治疗。对比两组治疗前后肠道菌群情况、炎性因子水平及生活质量。结果 观察组肠道内双歧杆菌、乳酸杆菌、拟杆菌均高于对照组,差异有统计学意义(P均<0.05),且酵母样真菌(2.84±0.49)CFU/g低于对照组,差异有统计学意义(t=7.720,P均<0.05)。观察组各项炎性因子水平均低于对照组,差异有统计学意义(P均<0.05)。观察组身体健康、心理健康、社会关系、环境评分均高于对照组,差异有统计学意义(P均<0.05)。结论 针对乙肝肝硬化患者采取双歧杆菌三联活菌联合保肝治疗,有利于改善肠道内的益生菌环境,降低其炎症反应,并使患者的生活质量稳步提高,值得进一步研究。

Objective To analyze the effect of simultaneous combination of bifidobacterium bifidum triplex and hepa-toprotective therapy in the treatment of hepatitis B cirrhosis.Methods 92 patients with hepatitis B cirrhosis admitted to the First Affiliated Hospital of Hainan Medical College from March 2020 to March 2023 were selected as the study subjects,and they were divided into the control group and the observation group after generating a randomized se-quence using the latest statistical software,with 46 cases each.The control group was treated with hepatoprotective therapy,and the observation group was treated with hepatoprotective therapy simultaneously combined with bifidobac-terium bifidum triplex.The level of intestinal flora,inflammatory factors and quality of life before and after treatment in the two groups were compared.Results Bifidobacterium bifidum,Lactobacillus and Bacteroides anomalies in the in-testinal tract of the observation group were higher than those of the control group,the differences were statistically sig-nificant(all P<0.05),and yeast-like fungi(2.84±0.49)CFU/g was lower than that of the control group,and the differ-ence was statistically significant(t=7.720,P<0.05).The levels of various inflammatory factors in the observation group were lower than those in the control group,and the differences were statistically significant(all P<0.05).The scores of physical health,mental health,social relationship and environment in the observation group were higher than those in the control group,and the differences were statistically significant(all P<0.05).Conclusion For patients with hepatitis B cirrhosis,taking bifidobacterium bifidum triplex combined with hepatoprotective therapy is conducive to improving the probiotic environment in the intestinal tract,decreasing its inflammatory response,and leading to a steady improve-ment in the quality of life of the patients,which is worthy of further study.